© 2008 Oxford University Press
This article appears in the following Nucleic Acid Symposium Series issue: Joint Symposium of the 18th International Roundtable on Nucleosides, Nucleotides and Nucleic Acids and the 35th International Symposium on Nucleic Acids Chemistry [View the issue table of contents]
Recent Developments in the Synthesis of RNA Oligonucleotides for Potential Therapeutic Applications.
lakDivision of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, Maryland, USA
*Corresponding Author.E-mail: Serge.Beaucage{at}fda.hhs.gov
Abstract
The 4-(N-dichloroacetyl-N-methylamino)benzyloxymethyl group for 2'-hydroxyl protection has been successfully employed in the solid-phase synthesis of AUCCGUAGCUAACGUCAUGG. The use of the 2'-Omethylthiomethyl (2'-O-MTM) protecting group in the development of a cost effective approach to RNA synthesis has been evaluated through the solid-phase synthesis of [2'-O-MTM U]19dT. Given the sensitivity of 2'-thioacetals to acidic conditions, the base-labile [2-(9- fluorenyl)propyl-2-oxy]carbonyl group for 5'-Oprotection of ribonucleosides has been designed to accommodate the synthesis of oligoribonucleotides functionalized with 2'-thioacetal groups.